For Healthcare Providers

Insurance Coverage

To help parents prevent severe RSV infection in high-risk infants, it’s important to know whether their insurance covers Synagis. Here are answers to some common questions your patients may ask you.

Q. What can my patients do to find out whether they are covered?A. While many health plans cover Synagis, the levels of coverage and the requirements for getting it can vary. Your patients can ask their employer and insurance company if Synagis is covered, and how it would be determined if their infant is eligible.

Return to top

Q. What if it's taking too long, or a patient's coverage was denied?A. Incomplete insurance forms can lead to delayed processing and denials. Make sure that your patient has provided all of their baby's relevant medical information. Any claims or reimbursement forms should be checked to see if anything is missing or incorrect before sending them.

Return to top

Q. There's a chance a patient might be denied coverage. What else can they do?A. It may be helpful to provide your patient with backup information. Studies on RSV, risk factors, or a letter of medical necessity—if appropriate—may help support your patient support their case. Refer them to the MedImmune Hotline. You may also call the Synagis Reimbursement Hotline at 1-877-480-8082.

Return to top

Q. Can a patient appeal a denial?A. If a patient's insurance plan denies coverage or reimbursement for Synagis, they may be able to appeal the decision. Their best plan of action is working together with you and their insurance company. Your office may be able to contact the Synagis Reimbursement Hotline at 1-877-480-8082 to discuss the appeals process.

Return to top

Q. What if a patient's insurance plan changes?A. Your patient should inform your office immediately if their insurance plan changes at any time. Many employers offer open enrollment during October and November so employees can make changes to their health plans. Patients enrolled in a state Medicaid program also need to let your office know before making any changes.

Return to top

Q. What if a patient doesn't have insurance, Medicare, or Medicaid, and can’t get coverage for Synagis?A. Eligible patients who can't get coverage can call the MedImmune Assistance Program at 1-877-480-8082 and apply for assistance.

Return to top

Q. What if a patient needs help with a high co-pay and deductible?A. Suggest that your patient contact the Patient Access Network Foundation, an indipendent non-profit organization that may be able to provide support, at 1-866-316-7263.

Return to top

 
 
 
MedImmune

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). Synagis has been used in more than one million children in the U.S. since its introduction in 1998. The first dose of Synagis should be administered prior to commencement of the RSV season. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Synagis should not be used in pediatric patients with a history of severe prior reaction to Synagis or its components. Cases of anaphylaxis were reported following re-exposure to Synagis and severe acute hypersensitivity reactions have also been reported on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reactions occur, caution should be used on re-administration of Synagis. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) have been reported.

In clinical trials, the most common adverse events occurring at least 1% more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever, and rhinitis. Cyanosis and arrhythmia were seen in children with CHD. There have also been post-marketing reports of injection site reactions.

Click here for full Prescribing Information.

Privacy Policy | Terms and Conditions | Site Map